A new method (nanosurgery and bioengineering treatment) of non-operative treatment of anterior cruciate ligament tears

Submission date	Recruitment status No longer recruiting	Prospectively registered	
21/03/2023		☐ Protocol	
Registration date	Overall study status	Statistical analysis plan	
12/04/2023	Completed	[X] Results	
Last Edited 07/05/2025	Condition category Injury, Occupational Diseases, Poisoning	Individual participant data	

Plain English summary of protocol

Background and study aims

Anterior cruciate ligament (ACL) tears account for 40%-50% of all ligamentous knee injuries. Most patients with ACL ruptures are treated with surgical procedures. In non-operative methods of ACL tears treatment, there is no objective, well-documented, repeatable, and standardized method. The current study aims to investigate ACL healing outcomes in patients who underwent non-operative, nanosurgery, and bioengineering treatment (NSBT).

Who can participate?

Patients with a traumatic knee history and confirmed ACL tears

What does the study involve?

Patients who meet all research criteria will be admitted to the trial and divided into 2 groups: the treatment group and the control group. Group I patients will be treated with a nanosurgery procedure with ultrasound-guided RP-hCM, RP-hCM is a modified platelet-rich plasma (PRP) injection. Group II patients will be treated with ultrasound-guided PRP injection into the joint capsule. The following variables in clinical assessment for all patients pre- and post-treatment were analyzed: WOMC scale, Lysholm knee scoring, VAS, and physical examination. All patients pre- and post-treatment were assessed by ultrasound and MRI examinations. Most of the patient groups were verified in the nano-scope procedure.

What are the possible benefits and risks of participating?

A benefit of participating is a shorter recovery period taking only 12 weeks instead of 9 months. Possible risks include local pain after NSBT, failure of NSBT and conversion to an operative reconstruction of the ACL.

Where is the study run from? Wasilczyk Medical Clinic (Poland)

When is the study starting and how long is it expected to run for? June 2014 to July 2023

Who is funding the study?
Wasilczyk Medical Clinic (Poland)

Who is the main contact? Mr Cezary Wasilczyk, wasilczyk.chirurg@gmail.com (Poland)

Study website

https://www.wasilczyk-usg.pl/

Contact information

Type(s)

Principal Investigator

Contact name

Mr Cezary Wasilczyk

ORCID ID

https://orcid.org/0000-0003-1628-3669

Contact details

Kosiarzy, 37/80 Warszawa Poland 02-953 +48 502200590 wasilczyk.chirurg@gmail.com

Additional identifiers

EudraCT/CTIS number

Nil known

IRAS number

ClinicalTrials.gov number

Nil known

Secondary identifying numbers

2015/NSBT/ACL

Study information

Scientific Title

Nano-surgical and bioengineering treatment of human anterior cruciate ligament tears with ultrasound-guided RP-hCM intake based on clinical, ultrasound, MRI, and nano-scope analyses

Study objectives

Nano-surgical and bioengineering treatment (NSBT) of human anterior cruciate ligament (ACL) tears with ultrasound-guided RP-hCM (rich plasma-human cell memory), a modified platelet-rich plasma that has potential cell memory, is a new way of non-operative ACL treatment

Ethics approval required

Old ethics approval format

Ethics approval(s)

Approved 18/11/2021, the bioethics committee of the regional medical chamber in Warsaw (Komisja Bioetyczna Okregowej Izby Lekarskiej W Warszowie; st. Pulowska, 18 02-512, Warsaw; +22 54 28 340, 42, 82; biuro@oilwaw.org.pl), ref: KB/1328/21

Study design

Randomized double-blind study

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Hospital

Study type(s)

Treatment

Participant information sheet

Not available in web format

Health condition(s) or problem(s) studied

Non-operative treatment of anterior cruciate ligament tears

Interventions

Nanosurgery and bioengineering treatment (NSBT) under ultrasound guidance. Clinical examprospective, blind comparison to the gold standard.

The study uses a simple randomization model - sequentially numbered opaque, sealed envelopes to conceal the allocation. Patients will be consecutively enrolled and assigned to the study groups. The trial is double-blind, meaning that patients are blinded to which treatment group they are admitted to and are unblinded after the 6-week follow-up visit. The patients, the data collectors and the assessors are blinded. An independent examiner is blinded to the nano surgical and injection side and study group.

All nanosurgery procedures are standardized and are done in ambulatory conditions under local anaesthesia in a sterile way. The patients are arranged in the stomach position using posterior access. ACL fibres are defined in the ultrasound view. Using a needle (0.6-0.8 mm x 70-80 mm) under ultrasound guidance percutaneous Rp-hCM ACL intake is performed into the joint capsule

exactly to the ACL ruptured fibers. The method of Rp-hCM and PRP preparation was standardized. The NSBT procedure was performed by an experienced orthopedic surgeon in ambulatory conditions.

The modes of delivery of the intervention are face-to-face and individual.

The intervention occurs in ambulatory conditions in a treatment room in Wasilczyk Medica Clinic. The medical staff are trained nurses and doctors. Ultrasound Alpinion E-CUBE 15 Platinum is for all interventions.

Intervention Type

Biological/Vaccine

Phase

Not Applicable

Drug/device/biological/vaccine name(s)

RP-hCM

Primary outcome measure

- 1. Pain measured using a visual analog scale (VAS) before treatment (1 day before NSBT) and after NSBT at baseline 24, 48 hours and next in 10 12 weeks
- 2. Patients' functional status in daily activities and pain assessed using the following measures before treatment (1 day before NSBT) and at the baseline 24, 48 hours and in 10 12 weeks:
- 2.1. The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)
- 2.2. The Lysholm Knee scoring
- 3. Clinical knee instability measured using a physical examination and in Lachman test at baseline

Secondary outcome measures

-

Overall study start date

01/06/2014

Completion date

01/07/2023

Eligibility

Key inclusion criteria

- 1. Positive Lachman and pivot shift test in physical examination
- 2. ACL tear confirmed in ultrasound and MRI examinations
- 3. No other coexisting injuries of the knee that would change treatment options to the operative procedure
- 4. Patient's signed informed consent to enrol in the trial

Participant type(s)

Patient

Age group

Mixed

Sex

Both

Target number of participants

30

Total final enrolment

25

Key exclusion criteria

- 1. Pregnancy
- 2. No patient signed informed consent to enrol in the trial

Date of first enrolment

01/01/2015

Date of final enrolment

30/07/2022

Locations

Countries of recruitment

Poland

Study participating centre Wasilczyk Medical Clinic Warsow

02-953 Warsaw ul Kosiarzy 37/80 Warszawa Poland 02-953

Sponsor information

Organisation

Wasilczyk Medical Clinic

Sponsor details

Kosiarzy 37/80 Warsaw Poland 02-953 +48 502200590 wasilczyk.chirurg@gmail.com

Sponsor type

Hospital/treatment centre

Website

https://www.wasilczyk-usg.pl

Funder(s)

Funder type

Hospital/treatment centre

Funder Name

Wasilczyk Medical Clinic

Results and Publications

Publication and dissemination plan

Planned publication in a high imact peer reviewed journal

Intention to publish date

30/05/2023

Individual participant data (IPD) sharing plan

The datasets generated during the current study will be published as a suplement to the results publication

IPD sharing plan summary

Published as a supplement to the results publication

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article		17/04/2025	07/05/2025	Yes	No
Results article		24/04/2024	07/05/2025	Yes	No